Zoetis, Inc. Stock Plummets to New 52-Week Low of $85.33

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 85.33 as of May 7, 2026. This significant drop highlights the stock's challenging performance over the past year, where it has recorded a decline of 51.18%. In contrast, the S&P 500 has shown a robust gain of 30.29% during the same period. With a market capitalization of USD 53,244 million, Zoetis maintains a price-to-earnings ratio of 20.00, indicating its valuation relative to earnings. The company boasts a strong return on equity of 80.42%, reflecting high management efficiency. Additionally, Zoetis has demonstrated a solid ability to service its debt, evidenced by a low debt-to-EBITDA ratio of 1.22 times. Despite the recent price decline, Zoetis has reported positive results for the last six consecutive quarters, with net sales growing at an annual rate of 8.16%. The stock's performance metrics, including a dividend yield of 1.71% and a price-to-book ratio of 15.98, suggest a complex financial landscape as the company navigates its current market position.